Answer
Kalydeco (ivacaftor) tablet monotherapy is indicated for people with cystic fibrosis and a G551D CFTR mutation who are at least 6 years old and weigh at least 25 kg.
Sources for this answer
- Kalydeco 150 mg film-coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 35Document updated
Sources checked